News

August 23, 2017August 23, 2017

AdAlta Presenting Data on Therapy Candidate AD-114 at Inaugural IPF Summit

AdAlta‘s investigative therapy AD-114, developed for the treatment of idiopathic pulmonary fibrosis (IPF), are in the spotlight at the inaugural IPF Summit Aug. 21-23 in Boston. The IPF Summit brings together leading researchers and pharmaceutical ... Read more

August 22, 2017August 29, 2017

North Carolina Advances in Stem Cell Therapy for Lung Diseases Could Lead to Clinical Trial Soon

COPD, Cystic Fibrosis, Idiopathic Pulmonary Fibrosis, News

University of North Carolina Health Care researchers have made strides toward a stem cell treatment for lung diseases such as pulmonary fibrosis, COPD, and cystic fibrosis. In fact, they are discussing ... Read more

August 21, 2017August 21, 2017

Prometic, SRAM to Jointly Advance 3 Fibrosis, Scleroderma Therapies for Booming Chinese Market

Idiopathic Pulmonary Fibrosis, News

Canada’s Prometic Life Sciences and Shenzhen Royal Asset Management (SRAM) will jointly manufacture, develop and commercialize three fibrosis and scleroderma therapies in China, the two companies announced. namely the drugs PBI-4050, PBI-4547 and PBI-4425. A new subsidiary, ... Read more

August 18, 2017August 18, 2017

Vaccination Against Lung Pathogens Vital for People with Lung Disease, American Lung Association Reminds

Asthma, COPD, News, Pneumonia

August is National Immunization Awareness Month, and the American Lung Association is reminding adults with serious lung diseases that the Centers for Disease Control and Prevention (CDC) recommends vaccination against common ... Read more

August 17, 2017August 17, 2017

Pulmonary Fibrosis Awareness Month Kicks Off with PFF Walk in Chicago

Idiopathic Pulmonary Fibrosis, News

September is Pulmonary Fibrosis Awareness Month, and the Pulmonary Fibrosis Foundation (PFF) has chosen Chicago’s Lincoln Park as the venue to launch its inaugural PFF Walk 2017 on Sept. 9. ... Read more

August 16, 2017August 16, 2017

FDA Approves Teva’s QVAR RediHaler Asthma Maintenance Inhaler

Asthma, News

Israel’s Teva Pharmaceutical Industries has won U.S. Food and Drug Administration (FDA) approval for its QVAR RediHaler breath-actuated inhaler for maintenance treatment of asthma as a prophylactic therapy in patients 4 years ... Read more

August 15, 2017August 15, 2017

Genentech’s Alecensa Granted Priority Review for First-line Treatment of ALK-positive Advanced NSCLC

News

The U.S. Food and Drug Administration (FDA) granted priority review to Genentech’s Alecensa (alectinib) as a first-line treatment for ALK-positive, locally advanced or metastatic NSCLC (non-small cell lung cancer). It also accepted ... Read more

August 14, 2017August 14, 2017

Potential Therapy, GLPG1690, Seen to Halt Worsening of Lung Fibrosis in Phase 2 Trial

Idiopathic Pulmonary Fibrosis, News

Topline results from a Phase 2a clinical trial show that GLPG1690 successfully halted the worsening of idiopathic pulmonary fibrosis (IPF) in patients, its developer, the Belgian biotechnology firm Galapagos, announced. A double-blind, randomized, placebo-controlled trial, ... Read more

August 11, 2017August 11, 2017

Pamrevlumab Can Slow Progression of Pulmonary Fibrosis, Phase 2 Clinical Trial Suggests

News

Pulmonary fibrosis patients taking pamrevlumab had less than half the decline in a measure of lung function over 48 weeks than those receiving a placebo, a Phase 2 clinical trial indicates. The ... Read more

August 10, 2017August 10, 2017

Three Lakes Partners Now Accepting Submissions for $1M IPF Healthcare Challenge

Idiopathic Pulmonary Fibrosis, News

Three Lakes Partners, a philanthropic venture committed to end idiopathic pulmonary fibrosis (IPF), has officially launched its $1 million IPF Catalyst Challenge and is now accepting submissions. The healthcare competition will award ... Read more